Compare MFA & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MFA | COLL |
|---|---|---|
| Founded | 1997 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | N/A | 2015 |
| Metric | MFA | COLL |
|---|---|---|
| Price | $9.82 | $34.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $11.05 | ★ $50.83 |
| AVG Volume (30 Days) | ★ 1.2M | 400.6K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | ★ 14.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | N/A | $6.07 |
| Revenue Next Year | $10.02 | N/A |
| P/E Ratio | ★ $7.75 | $20.21 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $8.39 | $23.23 |
| 52 Week High | $11.08 | $50.79 |
| Indicator | MFA | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 42.70 | 16.51 |
| Support Level | $9.76 | $34.30 |
| Resistance Level | $9.83 | $36.20 |
| Average True Range (ATR) | 0.23 | 1.59 |
| MACD | -0.03 | -0.70 |
| Stochastic Oscillator | 13.33 | 2.18 |
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.